Ignite Creation Date:
2024-05-06 @ 3:34 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04671615
Status:
COMPLETED
Last Update Posted:
2023-10-30
First Post:
2020-11-24
Brief Title:
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
DEMOGRAPHICS PATIENT CHARACTERISTICS TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS TREATED WITH PALBOCICLIB IN A REAL LIFE SETTING IN ISRAEL
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to understand the treatment patterns patients and their clinical outcomes in a real life setting in Israel This study was done in adult breast cancer patients who have started palbociclib combination treatment as per the national basket of health services in January 2018 until August 2020 for all lines of therapy
This study had included adult patients who were prescribed with palbociclib for their breast cancer which had spread to other parts of the body
Patients are followed for around 35 years
This study had included adult patients who were prescribed with palbociclib for their breast cancer which had spread to other parts of the body
Patients are followed for around 35 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None